Type 1 diabetes

Teresa Quattrin; Lucy D. Mastrandrea; Lucy S.K. Walker

doi:10.1016/S0140-6736(23)00223-4

Type 1 diabetes

Pediatrics

University College London

Research output: Contribution to journal › Review article › peer-review

199 Scopus citations

Abstract

Type 1 diabetes is a chronic disease caused by autoimmune destruction of pancreatic β cells. Individuals with type 1 diabetes are reliant on insulin for survival. Despite enhanced knowledge related to the pathophysiology of the disease, including interactions between genetic, immune, and environmental contributions, and major strides in treatment and management, disease burden remains high. Studies aimed at blocking the immune attack on β cells in people at risk or individuals with very early onset type 1 diabetes show promise in preserving endogenous insulin production. This Seminar will review the field of type 1 diabetes, highlighting recent progress within the past 5 years, challenges to clinical care, and future directions in research, including strategies to prevent, manage, and cure the disease.

Original language	English
Pages (from-to)	2149-2162
Number of pages	14
Journal	The Lancet
Volume	401
Issue number	10394
DOIs	https://doi.org/10.1016/S0140-6736(23)00223-4
State	Published - Jun 24 2023

Access to Document

10.1016/S0140-6736(23)00223-4

Cite this

@article{352cdc5cf61f443e9df91be3338d5912,

title = "Type 1 diabetes",

abstract = "Type 1 diabetes is a chronic disease caused by autoimmune destruction of pancreatic β cells. Individuals with type 1 diabetes are reliant on insulin for survival. Despite enhanced knowledge related to the pathophysiology of the disease, including interactions between genetic, immune, and environmental contributions, and major strides in treatment and management, disease burden remains high. Studies aimed at blocking the immune attack on β cells in people at risk or individuals with very early onset type 1 diabetes show promise in preserving endogenous insulin production. This Seminar will review the field of type 1 diabetes, highlighting recent progress within the past 5 years, challenges to clinical care, and future directions in research, including strategies to prevent, manage, and cure the disease.",

author = "Teresa Quattrin and Mastrandrea, \{Lucy D.\} and Walker, \{Lucy S.K.\}",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier Ltd",

year = "2023",

month = jun,

day = "24",

doi = "10.1016/S0140-6736(23)00223-4",

language = "English",

volume = "401",

pages = "2149--2162",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier B.V.",

number = "10394",

}

TY - JOUR

T1 - Type 1 diabetes

AU - Quattrin, Teresa

AU - Mastrandrea, Lucy D.

AU - Walker, Lucy S.K.

PY - 2023/6/24

Y1 - 2023/6/24

N2 - Type 1 diabetes is a chronic disease caused by autoimmune destruction of pancreatic β cells. Individuals with type 1 diabetes are reliant on insulin for survival. Despite enhanced knowledge related to the pathophysiology of the disease, including interactions between genetic, immune, and environmental contributions, and major strides in treatment and management, disease burden remains high. Studies aimed at blocking the immune attack on β cells in people at risk or individuals with very early onset type 1 diabetes show promise in preserving endogenous insulin production. This Seminar will review the field of type 1 diabetes, highlighting recent progress within the past 5 years, challenges to clinical care, and future directions in research, including strategies to prevent, manage, and cure the disease.

AB - Type 1 diabetes is a chronic disease caused by autoimmune destruction of pancreatic β cells. Individuals with type 1 diabetes are reliant on insulin for survival. Despite enhanced knowledge related to the pathophysiology of the disease, including interactions between genetic, immune, and environmental contributions, and major strides in treatment and management, disease burden remains high. Studies aimed at blocking the immune attack on β cells in people at risk or individuals with very early onset type 1 diabetes show promise in preserving endogenous insulin production. This Seminar will review the field of type 1 diabetes, highlighting recent progress within the past 5 years, challenges to clinical care, and future directions in research, including strategies to prevent, manage, and cure the disease.

UR - https://www.scopus.com/pages/publications/85153262995

U2 - 10.1016/S0140-6736(23)00223-4

DO - 10.1016/S0140-6736(23)00223-4

M3 - Review article

C2 - 37030316

AN - SCOPUS:85153262995

SN - 0140-6736

VL - 401

SP - 2149

EP - 2162

JO - The Lancet

JF - The Lancet

IS - 10394

ER -

Type 1 diabetes

Abstract

Access to Document

Other files and links

Fingerprint

Cite this